公开(公告)号：US07109168B1

公开(公告)日：2006-09-19

申请号：US10048307

申请日：2000-06-16

Applicant: David E. Wright ,  D. Elliott Parks

Inventor： David E. Wright ,  D. Elliott Parks

IPC: A61K38/16 ,  C07K7/08 ,  C07K14/00 ,  C07K1/00

CPC classification number: A61K38/10 ,  A61K38/16 ,  C07K5/0212 ,  C07K7/02 ,  C07K14/5415

Abstract: Retro-inverso peptides derived from leukemia inhibitory factor (LIF) having between 18 and about 40 amino acids and including the sequence shown in SEQ ID NO: 1. These peptides have the same activity as native LIF and also have neurotrophic activity. Because of the D-amino acid linkage in the peptides, they are less susceptible to proteolytic degradation in vivo.

Abstract translation: 衍生自具有18至约40个氨基酸的白血病抑制因子（LIF）的逆转肽，并且包括SEQ ID NO：1所示的序列。这些肽具有与天然LIF相同的活性并且还具有神经营养活性。 由于肽中的D-氨基酸连接，它们在体内不易于蛋白水解降解。

公开(公告)号：US07754688B2

公开(公告)日：2010-07-13

申请号：US11544507

申请日：2006-10-05

Applicant: David E. Wright ,  D. Elliott Parks

Inventor： David E. Wright ,  D. Elliott Parks

IPC: A61K38/10 ,  A61K38/00 ,  C07K2/00 ,  C07K7/08 ,  A61K38/02

CPC classification number: A61K38/10 ,  A61K38/204 ,  C07K5/0212 ,  C07K7/02

Abstract: This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO: 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.

Abstract translation: 本发明提供了使用衍生自具有15至约40个氨基酸的白细胞介素-6（IL-6）的逆转换肽的治疗方法，并且包括相对于SEQ ID NO：1反向逆转的序列，即其中 所述肽包含序列D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D -Ala-D-Leu-D-Ala-D-Glu。 本发明的肽具有与天然IL-6相同的活性并具有神经营养活性。 由于它们的D-氨基酸连接，本发明的肽也不太容易在体内蛋白水解降解。

公开(公告)号：US07135461B1

公开(公告)日：2006-11-14

申请号：US10048305

申请日：2000-06-16

Applicant: David E. Wright ,  D. Elliott Parks

Inventor： David E. Wright ,  D. Elliott Parks

IPC: A61K38/10 ,  C07K7/08 ,  A61K38/00 ,  A61K38/02 ,  C07K2/00

CPC classification number: A61K38/10 ,  A61K38/204 ,  C07K5/0212 ,  C07K7/02

Abstract: Retro-inverso peptides derived from interleukin-6 (IL-6) having between 17 and about 40 amino acids and including the sequence shown in SEQ ID NO: 1. These peptides have the same activity as native IL-6 and also have neurotrophic activity. Because of the D-amino acid linkage in the peptides, they are less susceptible to proteolytic degradation in vivo.

Abstract translation: 衍生自具有17至约40个氨基酸的白介素-6（IL-6）的逆转换肽，并且包括SEQ ID NO：1所示的序列。这些肽具有与天然IL-6相同的活性并且还具有神经营养活性 。 由于肽中的D-氨基酸连接，它们在体内不易于蛋白水解降解。

公开(公告)号：US07754690B2

公开(公告)日：2010-07-13

申请号：US11501975

申请日：2006-08-09

Applicant: David E. Wright ,  D. Elliott Parks

Inventor： David E. Wright ,  D. Elliott Parks

IPC: A61K38/16 ,  C07K7/08

CPC classification number: A61K38/10 ,  A61K38/16 ,  C07K5/0212 ,  C07K7/02 ,  C07K14/5415

Abstract: The invention provides methods of treatment using retro-inverso peptides derived from leukemia inhibitory factor (LIF) having between 18 and about 40 amino acids and including the sequence that is retro-inverso with respect to SEQ ID NO: 1. The peptides of the invention have the same activity as native LIF and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.

Abstract translation: 本发明提供了使用衍生自具有18至约40个氨基酸的白血病抑制因子（LIF）的逆转换肽的治疗方法，并且包括相对于SEQ ID NO：1的反向逆转序列。本发明的肽 具有与天然LIF相同的活性，并具有神经营养活性。 由于它们的D-氨基酸连接，本发明的肽也不太容易在体内蛋白水解降解。

公开(公告)号：US07115571B1

公开(公告)日：2006-10-03

申请号：US10048302

申请日：2000-06-16

Applicant: David E. Wright ,  D. Elliott Parks

Inventor： David E. Wright ,  D. Elliott Parks

IPC: A61K38/10 ,  A61K38/16 ,  C07K7/08 ,  C07K14/00 ,  C07K1/00

CPC classification number: C07K14/5403 ,  A61K38/10

Abstract: Retro-inverso peptides derived from interleukin-3 (IL-3) having between 12 and about 40 amino acids and including the sequence shown in SEQ ID NO: 1. These peptides have the same activity as native IL-3 and also have neurotrophic activity. Because of the D-amino acid linkage in the peptides, they are less susceptible to proteolytic degradation in vivo.

Abstract translation: 衍生自具有12至约40个氨基酸的白细胞介素-3（IL-3）的逆转肽，并且包括SEQ ID NO：1所示的序列。这些肽具有与天然IL-3相同的活性并且还具有神经营养活性 。 由于肽中的D-氨基酸连接，它们在体内不易于蛋白水解降解。